Peritoneal metastasis (PM) is often regarded as a less frequent pattern of spread; however,
collectively across all spectra of primary tumors, the consequences of PM impact a large …

Peritoneal surface malignancies (PSMs) are usually associated with a poor prognosis.
Nonetheless, in line with advances in the management of most abdominopelvic metastatic …

Background The OVHIPEC-1 trial previously showed that the addition of hyperthermic
intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery resulted in improved …

Importance Hyperthermic intraperitoneal chemotherapy (HIPEC) followed by interval
cytoreductive surgery (ICS) has shown survival benefits for patients with advanced-stage …

Simple Summary Advanced ovarian cancer is the leading cause of gynecological death with
a high rate of reoccurrence indicating the critical need for improved therapeutics …

Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive
surgery has been extensively studied in patients with peritoneal carcinomatosis, and it holds …

Ovarian cancer is one of the most common gynecological malignancies and has low survival
rates. One of the main determinants of this unfavorable prognosis is the high rate of …

Simple Summary Advanced ovarian cancer (Stages III-IV) continues to be one of the
gynecological tumors with the highest mortality. Standard treatment consists of debulking …

Simple Summary Peritoneal metastases have a poor prognosis, and one potential treatment
option is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy …

Simple Summary Treatment with intraperitoneal hyperthermic chemotherapy (HIPEC) has
been criticized in ovarian cancer due to the lack of prospective and randomized clinical trials …